Table 2.

Oncologic outcomes after hemigland cryoablation by D’Amico criteria PCa risk group

			PCa Risk Group
	Overall		Low		Intermediate		High
No. pts (%)	160		29	(18)	106	(66)	25	(16)
Median mos followup (IQR)	40	(20–59)	45	(22–74)	34	(19–56)	36	(19–57)
Median ng/ml PSA nadir (IQR)	0.9	(0.5–2.3)	1.2	(0.75–2.3)	0.86	(0.49–2.1)	0.8	(0.24–3.1)
Median mos to PSA nadir (IQR)	4	(3–8)	6	(3–11)	4	(3–8)	4	(3–8)
Median % PSA decrease (IQR)	83	(63–92)	76	(51–86)	84	(63–92)	85	(66–94)
No. greater than 70% PSA decrease (%)*	107	(67)	18	(62)	71	(67)	18	(72)
% 5-Yr survival:
Phoenix criteria biochemical failure-free	62		78		57		67
Clinically significant PCa-free on followup biopsy	70		87		64		74
Radical treatment-free†	89		95		86		96
ADT-free	95		100		96		81
Treatment failure-free‡	85		95		83		78
5-Yr repeat focal cryoablation-free	86		82		87		88

Five-year treatment failure-free survival, metastasis-free survival, cancer specific survival and overall survival were 100%.

^*Percent of PSA decreased at nadir = (PSA at entry – PSA nadir)/(PSA at entry × 100).

^†Radical treatment defined as any whole gland treatment.

^‡Treatment failure defined as any whole gland treatment, ADT initiation, metastasis and PCa specific mortality.